Indolent Lymphoma
Showing 26 - 50 of 5,238
Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022
Follicular Lymphoma, Mantle Cell Lymphoma Trial in New York (Ribavirin)
Terminated
- Follicular Lymphoma
- Mantle Cell Lymphoma
-
New York, New YorkWeill Cornell Medicine
Sep 20, 2021
Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)
Recruiting
- Indolent B-Cell Non-Hodgkin Lymphoma
- BI1206
-
Atlanta, Georgia
- +8 more
Mar 1, 2022
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)
Active, not recruiting
- Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
-
Nagoya, Aichi, Japan
- +5 more
Dec 10, 2021
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,
Completed
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +8 more
- PI3K inhibitor BKM120
- +3 more
-
Atlanta, Georgia
- +1 more
Jun 27, 2022
Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- EO2463
- +2 more
-
Boston, Massachusetts
- +9 more
Jul 26, 2022
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Non Hodgkin's Lymphoma Trial in Sacramento, Santa Rosa (Rituximab, Lenalidomide)
Active, not recruiting
- Non Hodgkin's Lymphoma
-
Sacramento, California
- +1 more
Nov 15, 2021
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 7, 2021
Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
-
Duarte, California
- +2 more
Mar 9, 2022
Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +11 more
- Biopsy
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker
Active, not recruiting
- Follicular Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 6, 2022
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma Trial in Australia, United States (NKX019)
Recruiting
- Lymphoma, Non-Hodgkin
- +9 more
- NKX019
-
Denver, Colorado
- +6 more
Jan 19, 2022
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical
Completed
- Multiple Myeloma
- +7 more
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Nov 2, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent
Completed
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +9 more
- Lenalidomide
- Rituximab
-
Houston, TexasM D Anderson Cancer Center
Sep 28, 2021
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,
Recruiting
- R/R CD19-Positive B-Cell Malignancies
- +2 more
- CNTY-101
- +2 more
-
Detroit, Michigan
- +1 more
Dec 21, 2022
Obinutuzumab in Chinese Real-world Patients With iNHL
Not yet recruiting
- Lymphomas Non-Hodgkin's B-Cell
-
Changzhou, Jiangsu, China
- +24 more
Jul 23, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))
Active, not recruiting
- Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
- Blinatumomab Expanded T-cells (BET)
-
Bergamo, ItalyASST - Papa Giovanni XXIII
Dec 22, 2021
Follicular Lymphoma (Gastric or Duodenal), Marginal Zone Lymphoma (Gastric or Duodenal) Trial in Münster (Radiation Therapy)
Recruiting
- Follicular Lymphoma (Gastric or Duodenal)
- Marginal Zone Lymphoma (Gastric or Duodenal)
- Radiation Therapy
-
Münster, North Rhine-Westphalia, GermanyDepartment of Radiation Oncology
Dec 1, 2021
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +9 more
- Cryosurgery
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)
Active, not recruiting
- Indolent B-cell Non-Hodgkin's Lymphoma
-
Anjo, Aichi, Japan
- +29 more
Dec 10, 2021